首页> 外文期刊>Thrombosis and Haemostasis: Journal of the International Society on Thrombosis and Haemostasis >A global assay of haemostasis which uses recombinant tissue factor and tissue-type plasminogen activator to measure the rate of fibrin formation and fibrin degradation in plasma.
【24h】

A global assay of haemostasis which uses recombinant tissue factor and tissue-type plasminogen activator to measure the rate of fibrin formation and fibrin degradation in plasma.

机译:止血的全球检测方法,它使用重组组织因子和组织型纤溶酶原激活剂来测量血浆中血纤蛋白形成和血纤蛋白降解的速率。

获取原文
获取原文并翻译 | 示例
           

摘要

The global assay of Overall Haemostasis Potential we previously described has been refined. The coagulation cascade in platelet-poor plasma is triggered by adding a minimal dose of recombinant tissue factor together with purified phospholipids and calcium; fibrinolysis is initiated by adding recombinant tissue type-plasminogen activator in a concentration similar to what can be obtained during thrombolysis. Numerical differentials of optical densities reflecting rates of fibrin formation and degradation are calculated by a new software, and the Coagulation Profile (Cp) and the Fibrinolysis Profile (Fp) are determined. The combined effect of these counteractive systems is expressed as a ratio of Cp to Fp, called the Overall Haemostasis Index. Commercially available coagulant-deficient patient plasma samples and plasma with various amounts of added PAI-1 are examined; changes of fibrin turbidity demonstrate that this assay can determine Cp and Fp in a physiologically relevant way. Increased Cp and decreased Fp in prothrombotic patients, as well as expected effects of heparin or a thrombin inhibitor on Cp and Fp, suggest that our method can detect hypercoagulability and assist in monitoring antithrombotic treatment. Ongoing studies will show whether this simple assay can be of value in clinical routine.
机译:我们先前描述的整体止血潜力的整体检测方法已经过完善。通过添加最小剂量的重组组织因子以及纯化的磷脂和钙来触发贫血小板血浆中的凝血级联反应。通过添加重组组织型纤溶酶原激活剂来启动纤维蛋白溶解,其浓度应与溶栓过程中获得的浓度相似。通过新软件计算反映纤维蛋白形成和降解速率的光密度的数值差异,并确定凝血曲线(Cp)和纤维蛋白溶解曲线(Fp)。这些反作用系统的综合作用表示为Cp与Fp之比,称为总止血指数。检查市售的缺乏凝结剂的患者血浆样品和具有各种添加量的PAI-1的血浆;纤维蛋白浊度的变化表明,该测定法可以以生理学相关的方式测定Cp和Fp。血栓形成前患者的Cp升高和Fp降低,以及肝素或凝血酶抑制剂对Cp和Fp的预期作用,表明我们的方法可以检测高凝性并协助监测抗血栓形成的治疗。正在进行的研究将表明这种简单的测定方法是否在临床常规中有价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号